SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending amid speculation that Panasonic's new EV battery tech could be linked to them and Tesla, sparking high trading volume. The community is buzzing about a potential partnership and the implications for solid-state battery technology, while some debate the impact of insider selling. Overall, sentiment appears bullish, with many anticipating significant upside.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following news of a significant partnership with Nvidia, including a substantial investment, which has ignited discussions about its implications for the competitive landscape in AI and data centers. Community members are weighing the potential benefits for Intel's turnaround and its foundry business, while also considering potential challenges and market dynamics within the semiconductor sector.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as the community discusses its potential shift toward AI and high-performance computing, sparked by recent CEO comments. Traders are closely watching key resistance levels, with many viewing the stock as undervalued compared to its peers in the mining sector and anticipating a possible short squeeze. Bullish sentiment is fueled by high trading volume and potential for significant upside if the company successfully executes its new strategy.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending amidst a significant price drop, with the community debating whether it's an oversold opportunity or a value trap. Recent news of increased competition and concerns about slowing growth are driving the negative sentiment, while long-term bulls cite strong fundamentals and potential for a rebound.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to its rebranding as Solmate and a $300 million private placement to establish a Solana digital asset treasury, sparking significant community discussion around its potential and comparisons to similar crypto treasury plays. The stock's volatile price action, including multiple trading halts, has traders debating its short-term direction and potential for further gains or sharp declines. Community members are actively discussing price targets, short squeezes, and the influence of large investors.

LimeWire is reshaping the creator economy, one step at a time.  The beloved platform that helped millions of users in the early 2000’s to discover their favorite music, is back - to once again reinvent how fans and artists share content and interact with each other.  LimeWire is a platform for content creators, artists and brands to create membership-based communities. Creators can build recurring revenue streams by offering fans exclusive access to their community and journey as an artist. Through blockchain technology, LimeWire makes exclusive content and assets ownable and tradeable, allowing fans to not only consume content but also to directly participate in the success of the creators they support.  The LimeWire token is an ERC-20 utility token deeply embedded into the LimeWire ecosystem, designed to provide a series of perks and benefits to holders as well as to enhance the user experience across the LimeWire platform, such as monthly token rewards, access to in person events and voting rights.   In mid-2022, LimeWire successfully closed a $10.4M strategic & private pre-sale of the LimeWire Token with a long list of strong backers including Kraken Ventures, Crypto.com Capital, GSR and Arrington Capital.

LimeWire

LimeWire ($LMWR.X) is trending as community members highlight recent news and speculate on potential exchange listings, viewing it as an AI play with significant growth potential. Despite some concerns about tokenomics, there's excitement around its low market cap, brand recognition and upcoming features, especially the AI video creator. The nostalgic appeal of the LimeWire name combined with its reinvention as an AI studio is also fueling interest.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending due to a mixed market reaction to its latest earnings report; while the company beat expectations, cautious guidance is fueling uncertainty. The community is debating whether cost-cutting is sustainable and how new tariffs will impact future profitability. Some investors are concerned about soft shipping demand and are looking for more clarity on the company's long-term strategy.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package, International Package, and Supply Chain Solutions. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The Supply Chain Solutions is involved in forwarding, logistics, Coyote, Marken, and UPS Mail Innovations. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is trending as investors assess the impact of factors like insider buying, potential union actions, and the termination of a plan to acquire Estafeta. Community members are weighing positive earnings sentiment against concerns about union labor costs and overall financial health. Some traders are considering UPS for its dividend yield and potential long-term value, while others are wary of near-term headwinds.

FactSet Research Systems Inc. (the Company or FactSet) is a global financial digital platform and enterprise solutions provider with open and flexible technologies that aims to supercharge financial intelligence. Since inception, global financial professionals have utilized the company's content and multi-asset class solutions across each stage of the investment process. FactSet's goal is to provide a seamless user experience spanning idea generation, research, portfolio construction, trade execution, performance measurement, risk management, reporting, and portfolio analysis, in which the company serves the front, middle, and back offices to drive productivity and improved performance. FactSet's flexible, open data and technology solutions can be implemented both across the investment portfolio lifecycle or as standalone components serving different workflows in the organization. FactSet is focused on growing the business throughout each of its three segments, the Americas, EMEA (formerly known as Europe), and Asia Pacific. FactSet revised its internal organization within each segment to offer data, products and analytical applications by firm type: Institutional Buyside, Dealmakers, Wealth, and Partnerships and CGS. The company believes organization by firm type better aligns with its clients, the long-term view of its business and commitment to investing for growth and efficiency. FactSet currently serves financial professionals, which include portfolio managers, investment research professionals, investment bankers, risk and performance analysts, wealth advisors and corporate clients. FactSet provides both insights on global market trends and intelligence on companies and industries, as well as capabilities to monitor portfolio risk and performance and to execute trades. The company combines dedicated client service with open and flexible technology offerings, such as a configurable desktop and mobile platform, comprehensive data feeds, an open marketplace and digital portals and application programming interfaces (APIs). The company’s revenue is primarily derived from subscriptions to products and services such as workstations, analytics, enterprise data, and research management. FactSet Research Systems was founded by Howard E. Wille and Charles J. Snyder in September 1978 and is headquartered in Norwalk, CT.

Factset Research Systems Inc.

Factset is trending due to a recent earnings report and full-year guidance, sparking discussions about the company's performance and future outlook. The community is analyzing the impact of softer guidance and potential disruption from competitors, including Fiscal.ai. Some investors are pointing to long-term support levels and valuation metrics, while others are wary of downside risk amid increased volatility.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASPI is trending as investors discuss the potential implications of its upcoming JSE listing and the delayed RedChip investor webinar. Community members are actively debating the timing of news regarding commercial shipments and the QLE spin-off, with some expressing concerns about potential dilution. Despite the uncertainty, the long-term potential of ASPI's isotope technology and strategic partnerships in the nuclear and semiconductor sectors remains a key talking point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services.&nbsp;CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia.&nbsp;It is not intended for&nbsp;the treatment of postvaccinal encephalitis or isolated vaccinia keratitis.&nbsp;The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT.&nbsp;The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication.&nbsp;The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has risen 33.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.

Equity

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep revenue drop in the fourth quarter.&nbsp;While Emergent swung to a profit, the earnings beat failed to offset concerns over its shrinking top line.The medical contract development and manufacturing firm posted adjusted net income of $0.05 per diluted share, a sharp reversal from the $0.77 per share loss a year earlier. Analysts had expected a loss of $0.43 per share.&nbsp;However, quarterly revenue fell to $194.7 million from $276.6 million a year ago, well below the consensus estimate of $249.5 million.For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.&nbsp;For 2025, the company projected revenue of $750 million to $850 million, significantly trailing the $1.11 billion analysts had expected.“We delivered favorable full-year financial results driven by our core products, all the while completing a series of strategic stabilization actions to strengthen our financial position ahead of plan,” CEO Joe Papa said.&nbsp;“This strong foundation enables Emergent to focus on profitable revenue growth and cash generation as we move forward with turnaround activities, a critical phase in our multi-year transformation plan.”Despite the revenue shortfall, retail traders on Stocktwits remained optimistic, with sentiment for EBS ending Monday in the ‘bullish’ zone.&nbsp;Many users focused on the company’s improving profitability rather than its shrinking revenue.&nbsp;One trader compared the current situation to a period before Emergent had its Narcan opioid overdose nasal spray in its portfolio, arguing that profitability was the key factor.<stembedurl>https://stocktwits.com/WinstonSmith33/message/606629996</stembedurl>Another user pointed to CEO Joe Papa’s comments on the earnings call, noting that the company’s 2025 guidance appeared “conservative.”&nbsp;<stembedurl>https://stocktwits.com/GrantDiaz/message/606587312</stembedurl>Some traders speculated that Emergent’s mpox vaccine sales had not yet been factored into the guidance.&nbsp;While the company’s smallpox vaccine has been used for mpox, it has not yet&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">received</a> formal FDA approval for that indication.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions shares</a> are down more than 28% year-to-date but have more than doubled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 40%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.


Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

The S&amp;P 500 Index, a broader gauge of stock market performance, finished the week ended Nov. 8 at a record high amid the euphoria over a decisive win for the Republican Party candidate Donald Trump in the 2024 presidential election.The 30-stock Dow Jones Industrial Average and the tech-heavy Nasdaq Composite also ended in uncharted territory.&nbsp;As the new week unfolds, earnings and economic data will once again dictate sentiment. About 91% of the S&amp;P 500 companies have reported already, and the cumulative earnings growth of S&amp;P 500 companies is now estimated at 5.3%,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_110824.pdf">according</a> to Factset.The first-tier economic data/events for the week include the October consumer and producer price inflation reports, due on Wednesday and Thursday, respectively,&nbsp; the October retail sales report due on Friday and speeches by a slew of Federal Reserve officials.As the new week kickstarts, the following stocks are eliciting the most bullish/bearish reactions from retailers on the Stocktwits platformMost BullishMarathon Digital Holdings, Inc. ($MARA)Bitcoin miner Marathon Digital generated the most bullish sentiment, apparently due to the strength seen in the cryptocurrency space, especially the Bitcoin ($BTC.X). The a<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-hits-record-high-on-sunday/cJ4gJ3oRax">pex crypto crossed the $80,000 threshold</a> on Sunday and the momentum continued unabated on Monday. Bitcoin rallied past the $81,000 mark early Monday.BlackRock, Inc. ($BLK)Asset manager BlackRock was in the news last Thursday as media reports&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/c811be5f-73aa-4565-8901-f0eacdbad0bc">said</a> the company is in discussions to buy a small equity stake in hedge fund Millennium Management. Millennium is one of the most profitable hedge fund and if the rumors prove to be true, it would mark the first time in the firm’s 35-year history that it is taking an outside investment, Financial Times reportedCoinbase Global, Inc. ($COIN)Cryptocurrency exchange Coinbase may also be riding the crypto strength. In late-October, the company reported an increase in its third-quarter revenue from $623 million in 2023 to $1.13 billion in 2024. But both the earnings per share and revenue trailed expectations due to a muted crypto trading environment.Emergent Biosolutions, Inc. ($EBS)&nbsp;Shares of Emergent Biosolutions, a contract development and manufacturing organization, have picked up some momentum following the company’s quarterly results announced late Wednesday. The stock has tacked on over 31% since then.Netflix, Inc. ($NFLX)Streaming giant Netflix hasn't had any company-specific news or analysts’ action to impact the stock. However, AMC Entertainment Holdings, Inc. ($AMC) said last week its third quarter benefited from a new deal with Netflix for prior seasons of AMC series called the AMC Collection.Most BearishBaidu, Inc. (BIDU)Chinese search giant Baidu drew negative sentiment from retailers. Friday, the stock shed nearly 5% amid muted reaction to additional China stimulus and fears concerning a Trump backlash on overseas companies. Media reports said Baidu will launch its new AI-powered smart glasses at the Baidu World Event in Shanghai on Tuesday. The negative sentiment may also be partly due to investor apprehensions over whether the company can give Meta Platforms, Inc.’s ($META) Ray Ban smart glasses a run for the money.Aurinia Pharmaceuticals, Inc. ($AUPH)Kidney drug company Aurinia failed to attract a buyer after activist hedge fund MKT Capital forced the&nbsp; company to explore strategic initiatives, including a sale. While reporting its financial results last week, the Canadian biotech announced its decision to cut 45% of its workforce in a bid to save cost.Pinduoduo, Inc. ($PDD)General skepticism toward China stocks and domestic competition may have dented sentiment toward Chinese online retailer Pinduoduo.Evolent Health, Inc. ($EVH)Shares of Evolent are languishing at multi-year lows following Friday’s 45%+ plunge in reaction to its lackluster quarterly results. The specialty care management services company that focuses on&nbsp;oncology, cardiology, and musculoskeletal markets in the U.S. was scouting for a buyer earlier this year.Checkpoint Therapeutics, Inc. ($CKPT)Waltham, Massachusetts-based Checkpoint Therapeutics, a clinical-stage,&nbsp;immunotherapy and targeted-oncology company, hasn’t had any stock-moving catalysts.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/fifth-third-executive-weighs-in-on-election-impact/cJ4ginFRaC">Fifth Third CFO Bryan Preston Sees Trump’s 2024 Presidential Election Win Double-Edged Sword</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Crypto rally has improved sentiment toward stocks with exposure to them.

10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week

As the new week unfolds, earnings and economic data will again dictate sentiment. 

Shares of Emergent Biosolutions ($EBS) soared 23% (3 pm ET) Thursday after the company reported strong third-quarter results, lifting retail sentiment.Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10, a whopping 1225.81% difference. Revenues stood at $293.8 million, up from $270.5 million last year, driven by operational improvements. Wall Street had estimated revenues at $290.33 million. In addition, it has raised its FY24 revenue outlook to $1.05B-$1.13B."Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," Emergent chief executive, Joe Papa, said in a statement, "We have successfully improved efficiencies and refocused our operations related to customer demand, generated value in our core medical countermeasures and NARCAN Nasal Spray businesses and refinanced our debt leading to increased revenue and cash flow.”Retail sentiment for the stock turned ‘extremely bullish’ from ‘neutral’ a day ago. Meanwhile, message volumes were at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_08_at_1_28_37_AM_1cc65c7185.png" alt="Screenshot 2024-11-08 at 1.28.37 AM.png" width="1300" height="290"><figcaption>EBS Sentiment meter and message volumes on Nov 7 as of 3:05 pm ET</figcaption></figure>Emergent is hoping to capitalize on the ongoing public health crises like the opioid overdose epidemic and the Mpox outbreak. On Thursday, it also named &nbsp;Simon Lowry, M.D., as chief medical officer and head of research and development. Lowry, who was previously CEO at Mysthera Therapeutics, will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety.One Stocktwits user suggested the stock could more than double in value over time, with the recent developments.<stembedurl>https://stocktwits.com/manutd123/message/591609601</stembedurl>Emergent’s stock is up 343.6% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;

Retail sentiment for the stock turned ‘extremely bullish’| Source: Pixabay

Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong

Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10.

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Emergent BioSolutions stock rises on mixed Q3 results, improved 2024 guidance, and news of a new trial for mpox treatment in Africa led by the CDC.
read more...

What's Going On With Emergent BioSolutions Stock Wednesday?

Emergent BioSolutions stock is trading higher after the company announced the closing of a $100 million asset-backed revolving loan facility.
read more...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$7.97
Prev Close	$7.79
Open	$7.94
Dividend Yield	0.00%
50-Day Moving Average	$7.76
Beta	2.20
Avg. Volume	1.41M
PE Ratio	3.24

52-Week High	$12.73
52-Week Low	$4.02
Market Capitalization	$423.61M
EPS (Annual)	-$3.60
Price to Book	0.80
Revenue Per Employee	$1.16M
Enterprise Value/EBITDA	N/A

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EBS News

EBS Emergent Biosolutions Inc